HEK293 is typically the cell line of choice for mammalian transient transfection due to their ease of transfection, high levels of protein expression and robust workflows. When proteins are being expressed for the purposes of therapeutic development, CHO cells tend to be the cell line of choice, as approximately 70% of licensed biotherapeutic proteins are produced in stably transfected CHO cells.